CD38 Expression in CD8+ T Cells Predicts Virological Failure in HIV Type 1-Infected Children Receiving Antiretroviral Therapy

Clinical Infectious Diseases

Volumn 38, Issue 3, 2004, Pages 412-417

  Resino, Salvador ^a   Bellón, José M ^a   Gurbindo, M Dolores ^a   Muñoz Fernández, M Ángeles ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CD38 ANTIGEN; CD8 ANTIGEN;

ARTICLE; CELL COUNT; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION RISK; INTERMETHOD COMPARISON; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; T LYMPHOCYTE; TREATMENT FAILURE; VERTICAL TRANSMISSION; VIROLOGY; VIRUS DETECTION; VIRUS LOAD;

ADOLESCENT; ADP-RIBOSYL CYCLASE; ANTI-HIV AGENTS; ANTIGENS, CD; ANTIGENS, CD38; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD8-POSITIVE T-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; HIV INFECTIONS; HIV-1; HUMANS; INFANT; MEMBRANE GLYCOPROTEINS; PROGNOSIS; REGRESSION ANALYSIS;

EID: 1042300267     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/380793     Document Type: Article

References (34)

1. + cells of children perinatally infected with human immunodeficiency virus type 1 infection surviving longer than five years. Pediatr Res 1998; 43:752-8.
2. + T lymphocyte subsets with the most commonly used markers to monitor HIV-1 infection in children treated with highly active antiretroviral therapy. AIDS Res Hum Retroviruses 2001; 17:525-32.
3. Schlesinger M, Peters V, Jiang JD, Roboz JP, Bekesi JG. Increased expression of activation markers on CD8 lymphocytes in children with human immunodeficiency virus-1 infection. Pediatr Res 1995; 38:390-6.
4. + cell levels. J Infect Dis 1994; 170:775-81.
5. + cytotoxic T cells express CD38 and HLA-DR antigens. J Immunol 1993; 150:3070-9.
6. +) cells and their relation to enhanced cytotoxic T-cell activity during human immunodeficiency virus infection. Cell Immunol 1991; 138:229-37.
7. Levacher M, Hulstaert F, Tallet S, Ullery S, Pocidalo JJ, Bach BA. The significance of activation markers on CD8 lymphocytes in human immunodeficiency syndrome: staging and prognostic value. Clin Exp Immunol 1992; 90:376-82.
8. + lymphocyte percent: a useful immunological marker for monitoring HIV-1-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14:158-62.
9. + cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16: 83-92.
10. +) T cells as a prognostic marker in vertically HIV-infected pediatric patients. Pediatr Res 2002; 51:740-5.
11. + T lymphocyte response to highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children: a prospective study. Clin Infect Dis 2003; 37:1216-25.
12. van Rossum AM, Geelen SP, et al. Results of 2 years of treatment with protease-inhibitor-containing antiretroviral therapy in Dutch children infected with human immunodeficiency virus type 1. Clin Infect Dis 2002; 34:1008-16.
13. ++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection. AIDS 2002; 16:589-96.
14. Vigano A, Saresella M, Rusconi S, Ferrante P, Clerici M. Expression of CD38 on CD8 T cells predicts maintenance of high viraemia in HAART-treated HIV-1-infected children: highly active antiretroviral therapy. Lancet 1998; 352:1905-6.
15. + lymphocyte activation status and plasma HIV RNA levels during antiretroviral therapy. AIDS 1998; 12:1267-73.
16. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication- competent HIV despite prolonged suppression of plasma viremia. Science 1997; 278:1295-300.
17. Resino S, Gurbindo M, Bellón J, Sanchez-Ramón S, Muñoz-Fernández M. Predictive markers of clinical outcome in vertically HIV-1-infected infants: a prospective longitudinal study. Pediatr Res 2000; 47:509-15.
18. Centers for Disease Control and Prevention. Revised classification system for HIV-1 infection in children less than 13 years of age. MMWR Morb Mortal Wkly Rep 1994; 43:1-13. Available at: http://www.cdc .gov/epo/mmwr/ preview/mmwrhtml/00032890.htm.
19. Centers for Disease Control and Prevention. Guidelines for use of antiretroviral agents in pediatric HIV infection. MMWR Morb Mortal Wkly Rep 1998; 47:1-43.
20. Sharland M, Gibb D, Giaquinto C. Current evidence for the use of paediatric antiretroviral therapy - and PENTA analysis. Paediatric European Network for the Treatment of AIDS Steering Committee. Eur J Pediatr 2000; 159:649-56.
21. Palella FJ, Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60.
22. Mocroft A, Barry S, Sabin CA, et al. The changing pattern of admissions to a London hospital of patients with HIV: 1988-1997. Royal Free Centre for HIV Medicine. AIDS 1999; 13:1255-61.
23. Borkowsky W, Stanley K, Douglas SD, et al. Immunologic response to combination nucleoside analogue plus protease inhibitor therapy in stable antiretroviral therapy-experienced human immunodeficiency virus-infected children. J Infect Dis 2000; 182:96-103.
24. Wintergerst U, Hoffmann F, Solder B, et al. Comparison of two antiretroviral triple combinations including the protease inhibitor indinavirin children infected with human immunodeficiency virus. Pediatr Infect Dis J 1998; 17:517-8.
25. Mueller BU, Nelson RP Jr, Sleasman J, et al. A phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection. J Infect Dis 1998; 177:557-64.
26. Wiznia A, Stanley K, Krogstad P, et al. Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: week 24 results of a randomized controlled trial - PACTG 377. Pediatric AIDS Clinical Trials Group 377 Study Team. AIDS Res Hum Retroviruses 2000; 16:1113-21.
27. Rutstein RM, Feingold A, Meislich D, Word B, Rudy B. Protease inhibitor therapy in children with perinatally acquired HIV infection. AIDS 1997; 11:1487-94.
28. Wellons MF, Ottinger JS, Weinhold KJ, et al. Immunologic profile of human immunodeficiency virus-infected patients during viral remission and relapse on antiretroviral therapy. J Infect Dis 2001; 183:1522-5.
29. Garcia F, Plana M, Vidal C, et al. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. AIDS 1999; 13:F79-86.
30. Dyrhol-Riise AM, Voltersvik P, Olofsson J, Asjo B. Activation of CD8 T cells normalizes and correlates with the level of infectious provirus in tonsils during highly active antiretroviral therapy in early HIV-1 infection. AIDS 1999; 13:2365-76.
31. + cell counts after successful virologie suppression. Clin Infect Dis 2002; 35:1005-9.
32. + T cells in human immunodeficiency virus-infected patients experiencing virologie treatment failure: role of changes in thymic output and T cell death. J Infect Dis 2001; 183:1009-16.
33. + subsets in acute Epstein-Barr virus infection: comparison with chronic human immunodeficiency virus disease. J Infect Dis 1998; 177:1083-7.
34. Komanduri KV, Luce JA, McGrath MS, Herndier BG, Ng VL. The natural history and molecular heterogeneity of HIV-associated primary malignant lymphomatous effusions. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 13:215-26.